Millennium Management
SLNO

Millennium Management’s Soleno Therapeutics SLNO Stock Holding History

Millennium Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$670K Sell
20,000
-7,000
-26% -$274K ﹤0.01% 4626
2025
Q4 		$1.25M Sell
27,000
-180,700
-87% -$9.91M ﹤0.01% 4325
2025
Q3 		$14M Buy
+207,700
New +$15.4M 0.01% 2043
2025
Q2 		– Sell
-341,800
Closed -$24.4M – 6293
2025
Q1 		$24.4M Buy
341,800
+336,800
+6,736% +$16.4M 0.01% 1328
2024
Q4 		$225K Buy
+5,000
New +$259K ﹤0.01% 5238
2024
Q3 		– Sell
-20,000
Closed -$816K – 6447
2024
Q2 		$816K Buy
+20,000
New +$848K ﹤0.01% 4246

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Millennium Management's SLNO Position: Q1 2026 in Review

Millennium Management reduced its Soleno Therapeutics (SLNO) stake by 51% in Q1 2026, selling an estimated $24.7M and leaving 606,513 shares worth $20.3M. The position accounts for 0.01% of the portfolio, ranked #1536.

Millennium Management first reported a position in SLNO in Q1 2020 and has held it in 17 quarters since. The position peaked at $66.2M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Millennium Management held 606,513 shares of Soleno Therapeutics worth $20.3M as of Q1 2026.
  • Millennium Management sold 629,808 Soleno Therapeutics shares in Q1 2026, an estimated $24.7M.
  • Soleno Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1536 holding.
  • Millennium Management first reported a position in Soleno Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • Millennium Management's Soleno Therapeutics position peaked at $66.2M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.